Literature DB >> 24307579

Inhibition of hepatitis C virus production by aptamers against the core protein.

Shali Shi1, Xiaoyan Yu, Yimin Gao, Binbin Xue, Xinjiao Wu, Xiaohong Wang, Darong Yang, Haizhen Zhu.   

Abstract

Hepatitis C virus (HCV) core protein is essential for virus assembly. HCV core protein was expressed and purified. Aptamers against core protein were raised through the selective evolution of ligands by the exponential enrichment approach. Detection of HCV infection by core aptamers and the antiviral activities of aptamers were characterized. The mechanism of their anti-HCV activity was determined. The data showed that selected aptamers against core specifically recognize the recombinant core protein but also can detect serum samples from hepatitis C patients. Aptamers have no effect on HCV RNA replication in the infectious cell culture system. However, the aptamers inhibit the production of infectious virus particles. Beta interferon (IFN-β) and interferon-stimulated genes (ISGs) are not induced in virally infected hepatocytes by aptamers. Domains I and II of core protein are involved in the inhibition of infectious virus production by the aptamers. V31A within core is the major resistance mutation identified. Further study shows that the aptamers disrupt the localization of core with lipid droplets and NS5A and perturb the association of core protein with viral RNA. The data suggest that aptamers against HCV core protein inhibit infectious virus production by disrupting the localization of core with lipid droplets and NS5A and preventing the association of core protein with viral RNA. The aptamers for core protein may be used to understand the mechanisms of virus assembly. Core-specific aptamers may hold promise for development as early diagnostic reagents and potential therapeutic agents for chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24307579      PMCID: PMC3911575          DOI: 10.1128/JVI.03312-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.

Authors:  C Tuerk; L Gold
Journal:  Science       Date:  1990-08-03       Impact factor: 47.728

Review 2.  Hepatitis C virus resistance to protease inhibitors.

Authors:  Philippe Halfon; Stephen Locarnini
Journal:  J Hepatol       Date:  2011-02-01       Impact factor: 25.083

3.  Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras.

Authors:  Lee Adam Wheeler; Radiana Trifonova; Vladimir Vrbanac; Emre Basar; Shannon McKernan; Zhan Xu; Edward Seung; Maud Deruaz; Tim Dudek; Jon Ivar Einarsson; Linda Yang; Todd M Allen; Andrew D Luster; Andrew M Tager; Derek M Dykxhoorn; Judy Lieberman
Journal:  J Clin Invest       Date:  2011-05-16       Impact factor: 14.808

Review 4.  The potential role of HCV core antigen testing in diagnosing HCV infection.

Authors:  George J Dawson
Journal:  Antivir Ther       Date:  2012-12-07

5.  Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients.

Authors:  Hiroko Shindo; Shinya Maekawa; Kazuki Komase; Ryota Sueki; Mika Miura; Makoto Kadokura; Kuniaki Shindo; Fumitake Amemiya; Takatoshi Kitamura; Yasuhiro Nakayama; Taisuke Inoue; Minoru Sakamoto; Shun-Ichi Okada; Yasuhiro Asahina; Namiki Izumi; Masao Honda; Shuichi Kaneko; Nobuyuki Enomoto
Journal:  Hepatol Int       Date:  2011-08-18       Impact factor: 6.047

6.  Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.

Authors:  Magali Bouvier-Alias; Keyur Patel; Harel Dahari; Stéphanie Beaucourt; Patrick Larderie; Lawrence Blatt; Christophe Hezode; Gaston Picchio; Daniel Dhumeaux; Avidan U Neumann; John G McHutchison; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

7.  Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics.

Authors:  Michael D Moore; Jonathan Cookson; Veronica K Coventry; Brian Sproat; Lorna Rabe; Ross D Cranston; Ian McGowan; William James
Journal:  J Biol Chem       Date:  2010-11-24       Impact factor: 5.157

8.  Core as a novel viral target for hepatitis C drugs.

Authors:  Arthur Donny Strosberg; Smitha Kota; Virginia Takahashi; John K Snyder; Guillaume Mousseau
Journal:  Viruses       Date:  2010-08-20       Impact factor: 5.818

9.  Innate host response in primary human hepatocytes with hepatitis C virus infection.

Authors:  Darong Yang; Nianli Liu; Chaohui Zuo; Shoahua Lei; Xinjiao Wu; Fei Zhou; Chen Liu; Haizhen Zhu
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

10.  Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles.

Authors:  Takahiro Masaki; Ryosuke Suzuki; Kyoko Murakami; Hideki Aizaki; Koji Ishii; Asako Murayama; Tomoko Date; Yoshiharu Matsuura; Tatsuo Miyamura; Takaji Wakita; Tetsuro Suzuki
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

View more
  14 in total

Review 1.  Trends in the Design and Development of Specific Aptamers Against Peptides and Proteins.

Authors:  Maryam Tabarzad; Marzieh Jafari
Journal:  Protein J       Date:  2016-04       Impact factor: 2.371

Review 2.  Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war?

Authors:  Da-Rong Yang; Hai-Zhen Zhu
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

3.  EPSTI1 Is Involved in IL-28A-Mediated Inhibition of HCV Infection.

Authors:  Xianghe Meng; Darong Yang; Rong Yu; Haizhen Zhu
Journal:  Mediators Inflamm       Date:  2015-06-03       Impact factor: 4.711

Review 4.  Use of Aptamers as Diagnostics Tools and Antiviral Agents for Human Viruses.

Authors:  Víctor M González; M Elena Martín; Gerónimo Fernández; Ana García-Sacristán
Journal:  Pharmaceuticals (Basel)       Date:  2016-12-16

5.  A DNA aptamer efficiently inhibits the infectivity of Bovine herpesvirus 1 by blocking viral entry.

Authors:  Jian Xu; Xixi Zhang; Shuanghai Zhou; Junjun Shen; Dawei Yang; Jing Wu; Xiaoyang Li; Meiling Li; Xiufen Huang; Joshua E Sealy; Munir Iqbal; Yongqing Li
Journal:  Sci Rep       Date:  2017-09-18       Impact factor: 4.379

Review 6.  Application of Aptamers in Virus Detection and Antiviral Therapy.

Authors:  Xinran Zou; Jing Wu; Jiaqi Gu; Li Shen; Lingxiang Mao
Journal:  Front Microbiol       Date:  2019-07-03       Impact factor: 5.640

Review 7.  Selection and applications of functional nucleic acids for infectious disease detection and prevention.

Authors:  Lin Zhu; Jiajun Ling; Zhi Zhu; Tian Tian; Yanling Song; Chaoyong Yang
Journal:  Anal Bioanal Chem       Date:  2021-01-28       Impact factor: 4.478

Review 8.  Aptamers for Anti-Viral Therapeutics and Diagnostics.

Authors:  Tae-Hyeong Kim; Seong-Wook Lee
Journal:  Int J Mol Sci       Date:  2021-04-17       Impact factor: 5.923

9.  miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT.

Authors:  Nianli Liu; Chaohui Zuo; Xiaohong Wang; Tianran Chen; Darong Yang; Jing Wang; Haizhen Zhu
Journal:  Oncotarget       Date:  2014-07-15

Review 10.  Oligonucleotide aptamers: promising and powerful diagnostic and therapeutic tools for infectious diseases.

Authors:  Qin Pan; Fengling Luo; Min Liu; Xiao-Lian Zhang
Journal:  J Infect       Date:  2018-05-07       Impact factor: 6.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.